Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IBC Pharmaceuticals, a majority-owned subsidiary of Immunomedics, has received a notice from the US Patent and Trademark Office that it will receive additional two US patents for Dock-and-Lock Technology.
Subscribe to our email newsletter
The patent application ‘Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology’ will issue as US Patent no. 7,906,118 on 15 March 2011.
The patent will cover cytokine-antibody complexes made by the DNL technology.
Additinally, the company will also receive US Patent no. 7,906,121entiled ‘Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and Uses,’ on 15 March 2011.
Immunomedics president and CEO Cynthia Sullivan said they are pleased to receive these new important patents, which cover a new class of agents, such as ’20-2b’, a DNL construct comprised of 4 interferon-a2b molecules conjugated to veltuzumab, their humanized anti-CD20 antibody in clinical trials.
"We are currently evaluating this construct as a potential new therapy for patients with CD20-expressing lymphomas, funded by a new grant from the National Cancer Institute’s Small Business Innovation Research program," Sullivan said.